SC79 is an inhibitor of Akt-PH domain translocation and a unique specific Akt activator. SC79 enhances Akt phosphorylation and activation in multiple cell types and in both receptor tyrosine kinaseand GPCR-mediated signaling. SC79 suppresses PHAKTM-GFP plasma membrane translocation, and enhances phosphorylation of all three Akt isoforms in HEK293, HeLa, HL60, NB4, and HsSulton (B cells) cells. SC79 reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. SC79 (0.04 mg/g, i.p.) inhibits the cytosolic activation of Akt in the permanent focal cerebral ischemia mouse model, and recapitulates the primary cellular function of Akt signaling, resulting in augmented neuronal survival.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 70 mg/mL|
BRAT1 deficiency causes increased glucose metabolism and mitochondrial malfunction.
So EY, et al. BMC Cancer. 2014 Jul 29;14:548. PMID: 25070371.
Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death.
Jo H, et al. Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10581-6. PMID: 22689977.
|Related Akt Products|
Afuresertib hydrochloride is an orally bioavailable, potent and ATP-competitive inhibitor of the serine/threonine protein kinase Akt with potential antineoplastic activity.
Miransertib, also known as ARQ 092, is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3).
GSK2141795 is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively (Clinical phase 1).
GDC-0068(RG 7440) 2Hcl is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.